SLEEFLUX: Gastroesophageal Reflux Disease After Laparoscopic Sleeve Gastrectomy

Sponsor
University of Warmia and Mazury in Olsztyn (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05486169
Collaborator
National Science Centre, Poland (Other)
50
1
13
3.9

Study Details

Study Description

Brief Summary

The planned research is to analyze the occurrence of gastroesophageal reflux disease (GERD) before and after sleeve gastrectomy (SG). The study includes patients with BMI above 40 kg / m2 without symptoms of GERD before surgery and any pathological changes in gastroscopy. The day before the surgery, patients will be tested with impedance pH measurement. Thereafter, patients will undergo SG according to standard technique. As part of the follow-up 6 months after the surgery, the pH-measurement test with impedance again will be performed again for evaluation of the occurrence of GERD after surgery. It was planned to include 50 people in the study.

The main aim of the study is to assess the frequency and quality of GERD in patients after SG.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Sleeve Gastrectomy
N/A

Detailed Description

According to World Health Organization data, almost 15% of people in the world are obese, and this is constantly growing. According to the available literature, an effective method of observation long-term treatment that allows for the permanent cure of obesity is surgical treatment. Currently sleeve gastrectomy (SG) is the most commonly performed procedure in the world. There are numerous evidence of the effectiveness of surgery in treating obesity and comorbidities, however, came along with the increase in the number of procedures performed, controversy arises, including the occurrence of gastroesophageal reflux disease (GERD) after surgery. As a consequence, GERD can lead to esophageal cancer. This problem wants to be dealt with in this study.

The planned research is to analyze the occurrence of GERD before and after SG. Down the study will include patients whose BMI is 40 kg / m2 and more who will be positive passed the qualification process for SG. The exclusion criteria are the occurrence of symptoms of GERD before surgery, pathological changes in gastroscopy - features of reflux oesophagitis, and the patient's lack of consent to participation in the study. On the eve of surgery, patients will be tested with impedance pH measurement. Is it non-invasive 24-hour examination consisting in measuring the pH and impedance of the esophagus allowing for the detection of reflux episodes and their accurate assessment - type, time. Currently this test is the gold standard for the diagnosis of GERD, including in patients asymptomatic. Thereafter, patients will undergo SG according to standard technique. As part of the follow-up 6 months after the surgery, the pH-measurement test with impedance again will be performed again for evaluation of the occurrence of GERD after surgery. It was planned to include 50 people in the study, which is good, satisfactory material for statistical analysis.

The main aim of the study is to assess the frequency and quality of GERD in patients after SG. Yet published works on this issue define the occurrence of GERD mainly on on the basis of an interview with the patient or changes in the gastroscopy examination, which does not allow definitive definition of the disease incidence. Often, the mileage may be left to the patient asymptomatic - e.g. in the case of neutral reflux, and changes in endoscopic examination may not yet be visible. Thus, the only effective method to assess the occurrence of GERD is to perform a pH-measurement test with impedance. Moreover a group of 50 people subjected to the tests will make it possible to try to determine the predisposing factors to the occurrence of GERD after surgery, which will enable further the order of taking actions to prevent its occurrence. The results of the research will be presented on a thematic basis scientific conferences, then published in one of the renowned journals research in this field.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Screening
Official Title:
Gastroesophageal Reflux Disease in Patients Before and After Laparoscopic Sleeve Gastrectomy - pH-impedance Monitoring
Anticipated Study Start Date :
Aug 1, 2022
Anticipated Primary Completion Date :
Jul 31, 2023
Anticipated Study Completion Date :
Aug 31, 2023

Outcome Measures

Primary Outcome Measures

  1. gastroesophageal reflux after sleeve gastrectomy [6 months]

    The main aim of the study is to assess the frequency and quality of gastroesophageal reflux disease in patients six months after sleeve gastrectomy. The reflux will be measured in each patient using 24-hour pH-impedance testing

Secondary Outcome Measures

  1. outcomes of sleeve gastrectomy [6 months]

    Each patient would have their body weight measured and asked about the resolution of comorbidities during the control visit six months after surgery

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • BMI above 40kg/m2

  • positive qualification process for laparoscopic sleeve gastrectomy

Exclusion Criteria:
  • symptoms of gastroesophageal reflux disease before the surgery

  • pathological changes in gastroscopy before the surgery

Contacts and Locations

Locations

Site City State Country Postal Code
1 UWM Olsztyn Poland 10-045

Sponsors and Collaborators

  • University of Warmia and Mazury in Olsztyn
  • National Science Centre, Poland

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Natalia Dowgiałło-Gornowicz, MD, PhD, assistant professor, University of Warmia and Mazury in Olsztyn
ClinicalTrials.gov Identifier:
NCT05486169
Other Study ID Numbers:
  • 2022/06/X/NZ5/00007
First Posted:
Aug 3, 2022
Last Update Posted:
Aug 3, 2022
Last Verified:
Aug 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Natalia Dowgiałło-Gornowicz, MD, PhD, assistant professor, University of Warmia and Mazury in Olsztyn
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 3, 2022